Company Estimates 3Q 2007 BioThrax Revenues of Approximately $42
ROCKVILLE, Md.--(BUSINESS WIRE)--Oct. 2, 2007--Emergent
BioSolutions Inc. (NYSE:EBS), announced today that on September 28,
2007 it completed an initial delivery of doses of BioThrax(R) (Anthrax
Vaccine Adsorbed) to the U.S. Department of Health and Human Services
(HHS) for inclusion into the strategic national stockpile (SNS). As a
result of this initial delivery of doses into the SNS, the company
estimates it will report approximately $42 million in BioThrax
revenues for the third quarter of 2007. This initial delivery was made
under a three-year agreement with HHS, signed on September 25, 2007,
to supply 18.75 million doses of BioThrax for placement into the SNS
for a firm fixed-price of $400 million.
R. Don Elsey, senior vice president and chief financial officer of
Emergent BioSolutions, commented, "We are pleased that we have begun
delivering doses of BioThrax to HHS for inclusion into the strategic
national stockpile under our new three-year supply contract. Taking
into account this initial delivery, we continue to anticipate total
deliveries to HHS of approximately 6 million doses by year-end."
About BioThrax(R) (Anthrax Vaccine Adsorbed)
BioThrax is the only FDA-approved vaccine for the prevention of
anthrax infection. It is approved by the FDA as a pre-exposure
prophylaxis for use in adults who are at high risk of exposure to
anthrax spores. BioThrax is manufactured from a culture filtrate, made
from a non-virulent strain of Baccillus anthracis and contains no dead
or live bacteria. BioThrax is administered by subcutaneous injection
in three initial doses followed by three additional doses, with an
annual booster dose recommended thereafter. Since 1998, approximately
20 million doses of BioThrax have been procured by the U.S.
government. During that time period, over 6.5 million doses have been
administered to over 1.6 million military personnel. BioThrax cannot
cause anthrax infection.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company
dedicated to one simple mission--to protect life. We develop,
manufacture and commercialize immunobiotics, consisting of vaccines
and therapeutics that assist the body's immune system to prevent or
treat disease. Our biodefense business focuses on immunobiotics for
use against biological agents that are potential weapons of
bioterrorism and biowarfare. Our marketed product, BioThrax(R)
(Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S.
Food and Drug Administration for the prevention of anthrax infection.
Our commercial business focuses on immunobiotics for use against
infectious diseases and other medical conditions that have resulted in
significant unmet or underserved public health needs. More information
on the company is available at www.emergentbiosolutions.com.
Safe Harbor Statement
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, including
statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and
objectives of management, including our performance under our contract
with HHS and future payments from HHS to us under the contract, and
any other statements containing the words "believes", "expects",
"anticipates", "plans", "estimates" and similar expressions, are
forward-looking statements. There are a number of important factors
that could cause the company's actual results to differ materially
from those indicated by such forward-looking statements, including our
plans to expand our manufacturing facilities and capabilities; the
rate and degree of market acceptance and clinical utility of our
products; our ongoing and planned development programs, preclinical
studies and clinical trials; our ability to identify and acquire or in
license products and product candidates that satisfy our selection
criteria; the potential benefits of our existing collaboration
agreements and our ability to enter into selective additional
collaboration arrangements; the timing of and our ability to obtain
and maintain regulatory approvals for our product candidates; our
commercialization, marketing and manufacturing capabilities and
strategy; our intellectual property portfolio; our estimates regarding
expenses, future revenue, capital requirements and needs for
additional financing; and other factors identified in the company's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and
subsequent reports filed with the SEC. The company disclaims any
intention or obligation to update any forward-looking statements as a
result of developments occurring after the date of this press release.
CONTACT: Emergent BioSolutions Inc.
Robert G. Burrows
Vice President, Investor Relations
Director, Corporate Communications
SOURCE: Emergent BioSolutions Inc.